Ampio Pharmaceutical (AMPE) 5.85 $AMPE
Ampio Pharmaceuticals (AMPE) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:04AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
AMPE: 5.85 (-0.05)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
Alpha Exposure - Seeking Alpha - Tue Jan 27, 12:52PM CST
We believe Ampio Pharmaceuticals (NYSEMKT: AMPE ) is a stock promotion that is run by management with an alleged history of fraud and is aggressively promoting itself in preparation for a secondary. AMPE is quickly running out of cash and needs to...
UNXL: 5.12 (-0.19), AMPE: 5.85 (-0.05)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
Ampio Pharmaceuticals (AMPE) Strong On High Relative Volume Today
at The Street - Tue Jan 27, 9:02AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 5.85 (-0.05)
Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
PR Newswire - Thu Jan 22, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
AMPE: 5.85 (-0.05)
Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 8:39AM CST
Ampio Pharmaceuticals, Inc. (AMPE) was a big mover last session, as the company saw its shares rise over 14% on the day.
AMPE: 5.85 (-0.05), IG: 10.57 (-0.12)
Ampio Pharma up after Vyrix presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 2:45PM CST
AMPE: 5.85 (-0.05)
Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Thu Jan 08, 6:57AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 5.85 (-0.05)
Luoxis to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 5.85 (-0.05)
Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014
PR Newswire - Thu Dec 04, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11th, 2014. The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.
AMPE: 5.85 (-0.05)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial
PR Newswire - Mon Dec 01, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.
AMPE: 5.85 (-0.05)
Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress
PR Newswire - Mon Nov 24, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the presentation of three clinical and preclinical studies showcasing its RedoxSYS(TM) Diagnostic System as a broadly applicable and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress. In all three studies, which were performed in collaboration with Luoxis' academic and pharmaceutical research partners, RedoxSYS was able to assess biologically relevant changes in ORP, allowing it to serve as a simple, rapid biomarker of global oxidative stress.
AMPE: 5.85 (-0.05)
Ampio off premarket on expansion of data analysis in STRUT trial
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:05AM CST
AMPE: 5.85 (-0.05)
Ampio updates status of clinical trials and manufacturing facility
PR Newswire - Wed Nov 12, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on its ongoing clinical trials.
AMPE: 5.85 (-0.05)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 84.01 (+1.12), PRGO: 150.90 (+0.22), AUXL: 36.47 (-0.06), DEPO: 18.38 (+0.20), AMPE: 5.85 (-0.05)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), TEVA: 56.77 (-0.58), AMPE: 5.85 (-0.05), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Will Ampio (AMPE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 9:01AM CDT
Will Ampio (AMPE) Continue to Surge Higher?
AMPE: 5.85 (-0.05)
Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
PR Newswire - Mon Oct 20, 7:00AM CDT
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that its academic collaborators will present several peer-reviewed posters highlighting the clinical and research potential for its novel RedoxSYS Diagnostic System, a first-in-class platform that measures oxidation-reduction potential (ORP) in the body in response to injury or illness. A poster demonstrating the clinical value of ORP as a clinical marker will be presented by Christopher V. Fanale, MD of Swedish Medical Center at the International Stroke Conference 2015, February 11-13, in Nashville, Tennessee. Three additional posters showcasing RedoxSYS' broad potential as a global, homeostatic measurement of oxidative stress will be presented at 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM) November 19-23, 2014 in Seattle, Washington.
AMPE: 5.85 (-0.05)
Ampio Pharmaceuticals (AMPE) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:04AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
AMPE: 5.85 (-0.05)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
Alpha Exposure - Seeking Alpha - Tue Jan 27, 12:52PM CST
We believe Ampio Pharmaceuticals (NYSEMKT: AMPE ) is a stock promotion that is run by management with an alleged history of fraud and is aggressively promoting itself in preparation for a secondary. AMPE is quickly running out of cash and needs to...
UNXL: 5.12 (-0.19), AMPE: 5.85 (-0.05)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
Ampio Pharmaceuticals (AMPE) Strong On High Relative Volume Today
at The Street - Tue Jan 27, 9:02AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 5.85 (-0.05)
Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
PR Newswire - Thu Jan 22, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
AMPE: 5.85 (-0.05)
Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 8:39AM CST
Ampio Pharmaceuticals, Inc. (AMPE) was a big mover last session, as the company saw its shares rise over 14% on the day.
AMPE: 5.85 (-0.05), IG: 10.57 (-0.12)
Ampio Pharma up after Vyrix presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 2:45PM CST
AMPE: 5.85 (-0.05)
Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Thu Jan 08, 6:57AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 5.85 (-0.05)
Luoxis to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 5.85 (-0.05)
Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014
PR Newswire - Thu Dec 04, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11th, 2014. The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.
AMPE: 5.85 (-0.05)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial
PR Newswire - Mon Dec 01, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.
AMPE: 5.85 (-0.05)
Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress
PR Newswire - Mon Nov 24, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the presentation of three clinical and preclinical studies showcasing its RedoxSYS(TM) Diagnostic System as a broadly applicable and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress. In all three studies, which were performed in collaboration with Luoxis' academic and pharmaceutical research partners, RedoxSYS was able to assess biologically relevant changes in ORP, allowing it to serve as a simple, rapid biomarker of global oxidative stress.
AMPE: 5.85 (-0.05)
Ampio off premarket on expansion of data analysis in STRUT trial
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:05AM CST
AMPE: 5.85 (-0.05)
Ampio updates status of clinical trials and manufacturing facility
PR Newswire - Wed Nov 12, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on its ongoing clinical trials.
AMPE: 5.85 (-0.05)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 84.01 (+1.12), PRGO: 150.90 (+0.22), AUXL: 36.47 (-0.06), DEPO: 18.38 (+0.20), AMPE: 5.85 (-0.05)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), TEVA: 56.77 (-0.58), AMPE: 5.85 (-0.05), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Will Ampio (AMPE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 9:01AM CDT
Will Ampio (AMPE) Continue to Surge Higher?
AMPE: 5.85 (-0.05)
Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
PR Newswire - Mon Oct 20, 7:00AM CDT
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that its academic collaborators will present several peer-reviewed posters highlighting the clinical and research potential for its novel RedoxSYS Diagnostic System, a first-in-class platform that measures oxidation-reduction potential (ORP) in the body in response to injury or illness. A poster demonstrating the clinical value of ORP as a clinical marker will be presented by Christopher V. Fanale, MD of Swedish Medical Center at the International Stroke Conference 2015, February 11-13, in Nashville, Tennessee. Three additional posters showcasing RedoxSYS' broad potential as a global, homeostatic measurement of oxidative stress will be presented at 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM) November 19-23, 2014 in Seattle, Washington.
AMPE: 5.85 (-0.05)
